The financial stakes are enormous:
Pfizer announced in July that it expects $33.5 billion in covid-19 vaccine revenue this year.
“We are confident in this vaccine and the third dose,
but you have to remember the vaccine efficacy study is still going on,
so we need all the evidence to back up that,” Jerica Pitts, Pfizer’s director
of global media relations, said Monday.
The financial stakes are enormous:
Pfizer announced in July that it expects $33.5 billion in covid-19 vaccine revenue this year.
Meanwhile, Pfizer recently said that if a third dose couldn’t combat the delta
or other variants, the drugmaker is poised to come up with a “tailor-made” vaccine within 100 days. >
https://khn.org/news/article/pfizer-ceo-albert-bourla-covid-booster-evidence-lacking
dru
Pfizer announced in July that it expects $33.5 billion in covid-19 vaccine revenue this year.
“We are confident in this vaccine and the third dose,
but you have to remember the vaccine efficacy study is still going on,
so we need all the evidence to back up that,” Jerica Pitts, Pfizer’s director
of global media relations, said Monday.
The financial stakes are enormous:
Pfizer announced in July that it expects $33.5 billion in covid-19 vaccine revenue this year.
Meanwhile, Pfizer recently said that if a third dose couldn’t combat the delta
or other variants, the drugmaker is poised to come up with a “tailor-made” vaccine within 100 days. >
https://khn.org/news/article/pfizer-ceo-albert-bourla-covid-booster-evidence-lacking
dru
